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Trinidad and Tobago (T&T) is a Caribbean island with a population of approximately 1.3 
million. T&T has one of the highest breast cancer mortality rates in the region.  Notably, a 
large proportion of breast cancer cases in T&T appear to occur at a young age, as nearly 
36% of breast cancers are diagnosed under the age of 50. It is known that a younger age at 
diagnosis can be associated with Hereditary Breast and Ovarian Cancer syndrome (HBOC). 
However, the prevalence of HBOC mutations remains unknown in T&T, as accessible health 
services for genetic counseling and testing in T&T currently are limited.  As such, our study 
aimed to determine the prevalence and spectrum of HBOC mutations among women with 
breast cancer in T&T who met National Comprehensive Cancer Network (NCCN) criteria for 
evaluation for HBOC syndrome to determine the need to include genetic counseling and 
testing in local oncology management in T&T.  
At the main oncology unit in T&T, female breast cancer patients who met the NCCN criteria 
were recruited for this study. We conducted interviews inquiring about their personal breast 
cancer diagnosis, as well as any relevant family history. This was followed by the collection 
of saliva samples using Oragene kits, which were then analyzed by Color Genomics Inc. for 
30 genes associated with hereditary cancers. Finalized results were returned to patients by 
genetic counselors from Color Genomics.  In total, 58 patients who met NCCN guidelines 
were sequenced and results were returned. They showed that of 58 samples, 15 patients 
tested positive for deleterious HBOC germline mutations: 9 - BRCA1, 3 - BRCA2, 1 – 
CHEK2, 1- PALB2 and 1 – PTEN, with an overall prevalence rate of 25.8%. This prevalence 
rate is remarkable, given that HBOC mutations among U.S. women with breast cancer are 
found in only 5-10% of patients. These initial results clearly demonstrate the need to include 
genetic counseling and testing in the local oncology management in T&T, as the 
identification of HBOC mutations can influence treatment options, as well as help identify 
family members who are at high risk for cancer predisposition. Ultimately, this 
implementation could help alleviate the country’s high incidence and mortality rates with 
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INTRODUCTION AND BACKGROUND 
Trinidad and Tobago (T&T) has one of the highest breast cancer rates in the 
Caribbean region. According to the T&T’s National Cancer Registry, breast 
cancer represents 30% of all new female cancer cases, and 24% of all female-
cancer related deaths. In addition, a large proportion of breast cancer cases in 
T&T appear to occur at a young age. During 1998-2007, 36% of breast cancer 
diagnoses were under the age of 50, with the rates of early initial diagnosis (<45 
years old) being twice as high (20%) than that found in the United States (10%) 
(1). 
Trinidad and Tobago is a twin island nation at the south-eastern area of the 
Caribbean. It lies about seven miles off the eastern coast of Venezuela, and 
consists of approximately 5,100 square kilometers. These islands have a 
population of over 1.3 million citizens with an average life expectancy of 71 
years. It is the second largest English speaking country in the Caribbean region, 
and its population comprises of a heterogeneous ethnic makeup predominantly 
of African and East Indian descent (2). 
According to the Pan American Health Organization (PAHO), cancer incidence 
and related mortality in the Latin America and the Caribbean (LAC) region have 
recently been increasing.  It is predicted that by 2030, 1.7 million cases of cancer 
will be diagnosed in this region, with over a million predicted to die each year 
from the disease. Breast cancer ranks as the most common cancer type for 
women, both in terms of new cancer cases and deaths. Of note, in LAC, a 
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greater proportion of breast cancer deaths occur in women under 65 years of age 
(57%), as compared to North America (41%).  
Figure 1: Image showing comparisons of statistics for Trinidad and Tobago versus the United 
States. Source: http://www.catholiclane.com/250px-nsamerica-pol1/ 
Hereditary Breast and Ovarian Cancer Syndrome (HBOC), classically 
characterized by germline mutations in tumor suppressor genes can be 
associated with a younger age of breast cancer diagnosis. There are several 
genes that are now recognized to be associated with HBOC, such as BRCA 1, 
BRCA 2, TP53, PTEN, STK11, CDH11, CHEK2, ATM, RAD50 and PALB2.  
These genes vary in genetic penetrance, as some lead to a higher estimated 
lifetime risk than others. For example, BRCA 1, BRCA 2, TP53, PTEN, STK11 
and CDH11 are all considered high-penetrance breast cancer susceptibility 
genes. Mutations in these highly penetrant genes carry an approximate 10-fold 
increase in the estimated lifetime risk of breast cancer as compared to the risk of 
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an average female. In contrast, genes such as CHEK2, ATM, RAD50 and PALB2 
can be considered moderate-penetrance breast cancer susceptibility genes, and 
they are associated with a 2 to 4 fold increased risk. While moderately penetrant 
genetic mutations  carry a lower estimated lifetime risk of developing breast 
cancer when compared to the highly penetrant genes, they remain clinically 
relevant and have the potential to alter screening and breast cancer treatment 
options.    
The most well known among the spectrum of recognized HBOC mutations are 
those which occur in the BRCA1 and BRCA2 genes. These genes are 
responsible for tumor suppressor proteins that function in double-strand DNA 
repair.  Therefore, they play a major part in maintaining the stability of cellular 
genetic material. If a mutation occurs in one of these genes, this can result in the 
decreased function of the respective protein product, which in turn assists in  
DNA damage. As a result, this leads to an increased risk of cancer(s) in the 
breast, ovaries, prostate, pancreas, as well as several other locations (3).  
HBOC mutations, including those in BRCA 1 and 2, are inherited in an autosomal 
dominant pattern. As such, a genetic mutation can be inherited via either parent, 
and in turn  each offspring of an affected parent has a 50% chance of acquiring 
the mutation. The estimated lifetime risk of developing breast cancer for an 
individual carrying a BRCA 1 mutation is 55% to 69% by the age of 70, whereas 
risks for BRCA 2 are slightly lower at 45%. These compare to the estimated 
lifetime risk of 12% for  the general female population. Likewise, for ovarian 
cancer, the estimated lifetime risk is 46% for BRCA 1 mutation carriers and 11-
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17% for BRCA 2. These again can be compared to the estimated lifetime risk of 
1.3% for the general female population (3). 
Another HBOC-associated mutation is the alteration in the PTEN gene, which is 
responsible for production of the PTEN protein, which functions in the 
dephosphorylation process in the AKT signaling pathway.  This is responsible for 
key processes in cell proliferation and regulation, and therefore, provides 
assistance in tumor suppression. A mutation in this gene results in the increased 
risk of several cancers including breast, endometrial and thyroid cancers. The 
increased lifetime risk of developing breast cancer in these mutation carriers is 
30-50%. This mutation, also autosomal dominant, is associated with Cowden 
syndrome, which includes the presence of non-malignant cancers, such as 
hamartomas, trichilemmomas, and papillomatous papules (4).  
In addition to the two genes mentioned above, there are the mutations which 
occur in TP53 (a gene which produces a protein linked to cell apoptosis and 
genomic stability). This  can result in Li-Fraumeni syndrome which increases the 
risk of breast cancer, soft tissue/bone sarcomas and glioblastomas (5). Carriers 
of this mutation have 56% chance of developing breast cancer by age 45, with 
the increased estimated lifetime risk being over 90%. Other highly penetrant 
mutations include  STK11, which carries a 32% chance of developing breast 
cancer by 60, and CDH1, which comes with an estimated lifetime risk of 39% for 
developing lobular breast cancer (6).  
With respect to the moderately penetrant breast cancer susceptibility genes, 
5 
 
CHEK2 and ATM usually each confer a lifetime risk of at least 20% for breast 
cancer. PALB2 mutations bestow an estimated lifetime risk of 35% for breast 
cancer (7), and RAD51C, RAD51D and BRIP1 each present an estimated 
lifetime risk of 5-10% for ovarian cancer (6).  
As a result of the increased risk associated with these genetic mutations, it is 
recommended that those who are considered at a higher risk of carrying one of 
these altered genes be recommended for genetic counseling and testing. In the 
United States, there are several options for genetic testing, which have 
progressed significantly over the last twenty years. These genetic tests started 
from expensive single-panel tests which targeted one gene and have evolved to 
affordable multi-panel options which incorporate dozens of genes analyzed 
simultaneously though next-generation sequencing technologies. 
At the moment, in the United States, HBOC testing is mostly based on family 
history and ancestry. Therefore, many medical personnel use various guidelines 
to determine if an individual is at a high risk for having an HBOC genetic 
mutation. The most commonly used guidelines are those provided by the 
National Comprehensive Cancer Network (NCCN) and US Preventative Services 
Task Force (USPSTF) (8) (9): 
These criteria usually include: 
• Breast/ovarian cancer diagnosis at a young age (usually before 50 years) 
• Multiple primary sites of tumors (such as bilateral breast cancer, or a history 
of breast cancer as well as ovarian cancer) 
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• Extensive one-sided family history of breast, ovarian, prostate or pancreatic 
cancers 
• Family history of genetic mutations 
• Ancestry inclusive of populations known to have higher rates of HBOC 
mutations (eg. Ashkenazi Jewish ancestry). 
In the United States, BRCA 1 and BRCA 2 account for about 50% of HBOC, and 
5% of all breast cancers. For ovarian cancers, these mutations account for 
approximately 15% of all ovarian cancer cases. However, it is shown that certain 
racial, ethnic and geographically-locked populations have a higher prevalence for 
the BRCA 1 and BRCA 2 mutations, such as the descendants of the Ashkenazi 
Jewish population, and several Scandinavian and Icelandic populations (3). For 
example, in 2010, a high prevalence of BRCA mutations was found in the 
Bahamas, which is a small Caribbean nation. These islands, which may have 
experienced geographic and reproductive isolation until the increased 
immigration patterns starting in the mid19th century (10), were found to have a 
high incidence of pre-menopausal women diagnosed with breast cancer. 
Donenberg and Hurley tested 214 unselected Bahamian women with invasive 
breast cancer for BRCA mutations, and the results showed that 23% of these 
unselected cases were positive for the BRCA mutation. Interestingly, many of the 
patients who tested positive in this study had one of six distinct BRCA 1 
mutations, leading to the conclusion that these were most likely founder 
mutations due to their historically isolated populations which had propagated 
isolated reproductive patterns (11).  
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As many Caribbean islands share the same cultural, geographical and 
immigration history as the Bahamian islands, one may wonder whether islands 
that experience younger ages of breast cancer diagnoses would have similarly 
high hereditary genetic attributions to their breast cancer cases, and if there is a 
resulting need for accessible genetic counseling and testing throughout the 
Caribbean region. Trinidad and Tobago, has reported a young average age of 
breast cancer diagnoses. However, the prevalence and spectrum of the HBOC 
mutations in the country are unknown.  
One of the barriers to understanding the contribution of HBOC mutations in the 
breast cancer population in T&T is the limited access to genetic counseling and 
testing for the local population. The structure of Trinidad and Tobago's health 
system is mainly divided into two segments: public (which is free to the citizens) 
and private (which is paid out of pocket by the citizens). However, currently 
genetic testing is only available through the private sector of the health care 
system at a cost of$1500 - $2000 USD. Therefore, there are no options for this 
test in the public sector, and as a result, many patients and their families are not 
able to afford the genetic test.  
This is in stark contrast to the services provided in the United States and other 
developed countries who provide genetic consultation for high risk patients, 
followed by genetic testing, which is either covered by insurance or can be 
directly purchased at a reasonable price (approx. $250 - $500USD). Genetic 
testing has been proven useful in the United States, as the identification of 
HBOC mutations can influence treatment options in cancer patients (12), as well 
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as help identify family members who are at higher risk for having them. These 
can lead to prophylactic interventions which have been proven to reduce the risk 
of developing future cancer(s) should they test positive for a harmful mutation 
(13) (14).  
Therefore, with Trinidad and Tobago’s high breast cancer mortality and average 
young age of breast cancer diagnosis, our main aim was to determine whether 
these services, which have been beneficial in developed countries, should be 
implemented in this country.  
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STATEMENT OF PURPOSE 
 
With the young age of breast cancer diagnosis in Trinidad and Tobago coupled 
with the limited access to genetic testing, this project sought to determine if 
screening for HBOC mutations should be made more accessible to the 
population of Trinidad and Tobago.  
This main purpose was accomplished by completing the following two aims: 
1. Investigate the prevalence and spectrum of HBOC mutations in T&T’s 
breast cancer population.  
2. Determine the proportion of the general female population who met 
criteria for having a high risk of carrying a BRCA mutation, and therefore 
would potentially benefit from a referral for further genetic counseling 
and testing according to U.S. national guidelines. 
Through these aims, we examined the need to include genetic testing 






AIM ONE: Investigate the prevalence and spectrum of HBOC mutations in 
T&T’s breast cancer population.  
This portion of the project was conducted in the main cancer institution of the 
public health sector - the National Radiotherapy Center of Trinidad and Tobago. 
Recruitment focused on female breast cancer patients over 18 years, who met 
the National Comprehensive Cancer Network (NCCN) criteria for genetic 
counseling and testing. The patients were recruited either through doctor 
referrals or chart reviews.   
The NCCN criteria are stated below (15): 
• Diagnosed ≤45 years 
• Diagnosed ≤50 years with:  
o An additional breast cancer primary – (this can either be bilateral or 
a separate ipsilateral breast cancer) 
o ≥1 close blood relative (ie. first, second or third degree)  with breast 
cancer at any age  
o ≥1 close relative with pancreatic cancer  
o ≥1 close relative with prostate cancer (Gleason score ≥7)  
• Diagnosed ≤60 years with a:  
o Triple negative breast cancer  
• Diagnosed at any age with:  
o ≥1 close blood relative with breast cancer diagnosed ≤50 years 
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o ≥2 close blood relatives with breast cancer at any age  
o ≥1 close blood relative with ovarian cancer at any age 
o ≥2 close blood relatives with pancreatic cancer and/or prostate 
cancer (Gleason score ≥7) at any age  
o A close male blood relative with breast cancer  
o Personal history of ovarian cancer  
We conducted interviews inquiring about their personal breast cancer diagnosis, 
and collected relevant family history.  
The specific questions were as follows: 
GENERAL QUESTIONS 
1. Name 
2. Current Age 
3. Age of Diagnosis of breast cancer 
4. Self-reported Race/Ethnicity 
 
FAMILY HISTORY: 
1.  Family history of breast cancer (include age of diagnosis) 
2.  Family history of breast cancer before 50 (include age of diagnosis) 
3. Family history of bilateral breast cancer (include age of diagnosis for each) 
4. Family history of ovarian cancer (include age of diagnosis) 
5. Family history of multiple primary cancer diagnoses (include age of 
diagnosis for each) 





Each patient was given pre-test genetic counseling to ensure that they 
understood the entire genetic testing process, as well as the benefits and risk of 
the test. Participants each signed a consent form (details below in ethical 
considerations), and were assured that they could withdraw from the study at any 
point, which would not affect their current care at NRC. 
Next, each patient gave a saliva sample using the Oragene DNA sample 
collection kit (OG-250 format, DNA Genotek, Kanata, ON, Canada). This sample 
was then sent to the Color Genomics lab in California, United States for genetic 
sequencing,  using their standard 30 gene- panel which covers most clinically 
relevant hereditary cancer syndromes and includes the major HBOC-associated 
genes.  The genes investigated were APC, ATM, BAP1, BARD1, BMPR1A, 
BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A (p14ARF), CDKN2A 
(p16INK4a), CHEK2, EPCAM, GREM1, MITF, MLH1, MSH2, MSH6, MUTYH, 
NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, SMAD4, 
STK11, TP53. Full methods can be found in Appendix 1. 
To ensure that results were returned in a safe and informative manner, post-test 
counseling provided by a Color Genomics genetic counselor  either by phone or 
in person. The patients were given copies of their results to be shared with their 
personal physicians, and they received written educational material summarizing 
the topics discussed in the genetic counseling meeting. Patients were 
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encouraged to bring family members to the sessions, and first degree relatives of 




 AIM TWO: Determine the proportion of the general population, who met the 
criteria for having a high risk of carrying the BRCA mutation. 
In order to estimate the proportion of the general female population without a 
cancer diagnosis at a high risk of having the BRCA mutation, we used data from 
the T&T’s Cancer Society.  Paper medical records, were obtained for 1807 
women over the age of 18 years, without a personal history of breast cancer, 
who came into this center between 2010-2013 for preventative screenings such 
as mammograms and pap smears.  Family history criteria which were associated 
with an increased likelihood of having a BRCA mutation were extracted. These 
were taken from the U.S. National Institutes of Health/National Cancer Institute 
(NIH/NCI), which were guided by the US Preventative Services Task Force, as a 
screening method to capture those who should be evaluated by a genetic 
counselor (3). These included: 
• Three or more first or second degree relatives diagnosed with breast 
cancer or ovarian cancer 
• Two first degree relatives diagnosed with breast cancer, with one below 
age 50 
• An immediate family member with bilateral breast cancer 
• A relative diagnosed with ovarian cancer (regardless of age at diagnosis) 
• A combination of two or more first- or second-degree relatives diagnosed 
with both breast and ovarian cancer  (regardless of age at diagnosis) 




Ethics committee approvals were sought by the Human Investigation Committee 
(HIC) at Yale, as well as the local ethics committee in Trinidad and Tobago at the 
Northwest Regional Health Authority.   
For this study, the potential risk was minimal in terms of sample acquisition and 
data collection. Saliva collection posed minimal risk to participants, and medical 
data was kept in secured areas. All patients were required to sign informed 
consent which reviewed the personal (and for their family members) benefits, risks 
and limitations of undergoing genetic testing provided through Color Genomics. 
Color Genomics is compliant with Health Insurance Portability and Accountability 
Act of 1996.   
Participants were asked to acknowledge and consent to the following statements: 
• I am the individual providing the sample and I am at least 18 years of age 
• I understand that I have the choice to store my genetic sample with Color 
• I understand that I should not use Color if I have an allogenic bone marrow 
transplant (bone marrow from a donor), a blood transfusion within 7 days 
prior to providing a sample, or have an active hematologic malignancy such 
as leukemia, lymphoma or multiple myeloma.  
• I understand that these test results will not tell me whether or not I have or 
will get disease in the future. These results will only tell me about my 
hereditary risk related to disease or other genetic traits.  
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• I understand that I should not make any medical decisions based on these 
results by myself, and that Color recommends that I consult with my 
healthcare provider to create a personalized screening and prevention plan. 
• Genetic counseling services are available to me via Color at no additional 
charge. 
• Color will donate my de-identified variants found to public databases like 
NCB’s ClinVar, where anonymous genetic information will be accessible to 
researchers to better understand the connection between genetics and 
disease. 
Participants were given the opportunity to ask questions, as well as withdraw at 














AIM ONE: Investigate the prevalence and spectrum of HBOC mutations in 
Trinidad and Tobago’s breast cancer population.  
At the National Radiotherapy Center, 150 female breast cancer patients were 
initially approached for participation in the study based on meeting NCCN criteria 
for further genetic counseling and testing. Of those, 60 patients were ultimately 
enrolled into the study for genetic sequencing and interviewing based on their 
interest and availability to participate.  At Color Genomics, 58 patient samples 
were completely processed and analyzed, but two did not pass quality control 
and therefore were not completed. Table 1 below shows characteristics of the 
patients tested, and Table 2 stratifies the patients based on test results. 
This study found a prevalence rate of 25.8 % for the HBOC mutations tested in 
the multi-gene panel. Out of the 15/58 positive results, there were 9 BRCA1 
mutations, 3 BRCA2, 1 PTEN, 1 PALB2 and 1 CHEK2 mutations (Figure 2), 
distributed throughout the islands as shown in Figure 3. . 
Our positive patients are further described below (Table 3) showing their 
respective self-reported ethnicities, personal cancer histories, genetic sequence 
details, as well as their associated family history. Of note, in our 15 positive 
patients, only two were related (Proband 1-1 and 1-2). They were a 









Characteristics N Proportion 
Mean Age (Range) 47 (19-68)  
   
Ages   
<19 1 0.02 
20-29 2 0.03 
30-39 14 0.24 
40-49 15 0.26 
50-59 18 0.31 
≥60 8 0.14 
Ethnicity   
Afro-Caribbean 17 0.29 
East Indian  17 0.29 
Chinese 2 0.03 
Mixed/Other 22 0.39 
Family History   
Yes 35 0.60 
No 23 0.40 
19 
 
Table 2: Further classification of patients enrolled in the study according to self-




POSITIVE  VARIANTS OF 
UNCERTAIN 
SIGNIFICANCE  (VUS)  
NEGATIVE  
Total 15 16 27 
ANCESTRY (Self – 
Identified)  
   
       African  6 (0.35)  3 (0.12)   8 (0.53)  
       East Indian  5 (0.29)  6 (0.35)  6 (0.35)  
       Mixed  4 (0.17)  7 (0.29)  13 (0.54) 
AGE    
<20  0 (0.00)   0 (0.00)  1 (0.04)  
20-29  2 (0.13)  0 (0.00)  0 (0.00)  
30-39  3 (0.20)  5 (0.31)  8 (0.30)  
40-49  4 (0.27)  8 (0.50)  6 (0.22)  
50-59  5 (0.33)  3 (0.19)  9 (0.33)  




Table 3:  Characteristics of the enrolled patients who tested positive for HBOC genetic mutations  
P = paternal   Br.Ca = breast cancer   Thy = Thyroid cancer   Endo = endometrial cancer 
M= maternal   CRC = colorectal cancer 
*Proband ID 1-1 and 1-2 is a mother/daughter pair (the only related participants) 
+ c.HGVS – Human Genome Variation Society mutation description on the chromosomal level  




















45 Br.Ca c.4183C>T p.Gln1395* 
Pathogenic 
by 4 labs 
Ductal 
Carcinoma 
• Son – testicular (17) 
• Daughter – breast (34) 







34 Br.Ca c.4183C>T p.Gln1395* 
Pathogenic 
by 4 labs 
Ductal 
Carcinoma 
• Brother – testicular (17) 
• Mother – breast (57) 
• Aunt (P) – breast (75) 





















by 4 labs 
Ductal 
Carcinoma 
• Sister – breast (40) 
• Aunt (M) – leukemia (40) 
• Aunt (P) – breast (42) 
• Aunt (P) – colon (50) 
• Aunt (P) – colon (55) 











by 4 labs 
Ductal 
Carcinoma 
• Mother – breast (57) 




















African 28 Br.Ca c.1630C>T p.Gln544* 
Pathogenic 
by 3 labs 
Ductal 
Carcinoma 
• Father – lymphoma (57) 
• Uncle (M) – Lung  
• Paternal Aunt – breast (50) 
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Ductal 
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by 8 labs 
Ductal 
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African 48 Br.Ca c.4327C>T p.Arg1443* 
Pathogenic 















by 3 labs 
Ductal 
Carcinoma 
• Brother – lung (50) 
• Father – breast (50) 




















12 PTEN African 





by 4 labs 
Ductal 
Carcinoma 












• Mother – cervical (72) 
• Father – unknown 






• Sister - breast (20) 
• Mother -Breast (50) 
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Figure 2:  Distribution of HBOC genes found in patient sample. 










The average age of diagnosis for patients with HBOC mutations was 39.8 (range 
22-56). For BRCA1 it was 36.5 years (range 23-48), and for BRCA 2 it was 36.3 
years (range 22-48). For HBOC positive patients, the age ranges were:  two out 
of fifteen (0.13) for 18-29 years, three out of fifteen (0.2) for 30-39 years, four out 
of fifteen (0.27) for 40-49 years, five out of fifteen (0.33) for 50-59 years and one 
out of fifteen (0.07) for 60 and over. There was a Variant of Uncertain 
Significance (VUS) rate of 27.6%, and a negative rate of 46.6% 
With respect to subtypes of breast cancer, all the HBOC mutation carriers had 
invasive ductal carcinoma. Most common ethnicity among mutation carriers were 
those that self-identified as being of African descent (0.35) followed by those of 
East Indian descent (0.29). In BRCA 1 carriers, most common self-identified 
ethnicity was African descent (0.66). With respect to BRCA 2, most common self-
identified ethnicity was Mixed (0.66), which to the patients meant 
African/Hispanic and African/East Indian.  
In terms of family history, eight out of twelve (0.66) BRCA mutation carriers 
reported having some form of family history of cancer, six out of twelve (0.50) 
had at least one first degree relative with breast, ovarian or prostate cancer, five 
out of twelve (0.42) had extensive family history of cancer (including breast, 
ovarian or prostate) - of three or more first/second degree relatives. One BRCA 2 
patient had a first degree male relative with breast cancer. One BRCA 1 patient 
had a family history of ovarian cancer (second degree relative). 
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The patient with the PTEN mutation did have multiple primary tumors suggestive 
of Cowden syndrome (breast, endometrial, and thyroid), with several of the 
characteristic benign tumors such as skin hamartomas. She had a family history 
of a brother with prostate cancer (although she was unsure of his age of 
diagnosis). Previously she had tested negative on a sole BRCA-mutation panel. 
The patient with the CHEK2 mutation was diagnosed with breast cancer, and had 
a family cancer history for both parents (mother: cervical and father: unknown). 
The patient with the PALB2 mutation had a sister and mother both diagnosed 





AIM TWO: Determine the proportion of the general population, who met the 
criteria for having a high risk of carrying the BRCA mutation. 
Chart reviews were conducted from 1807 records at the Trinidad and Tobago 
Cancer Society, for women without a history of breast cancer diagnosis. The 
characteristics of the 520/1807 patients who reported having some family history 
are shown in Table 4. 
Table 4: Characteristics from chart extractions describing clients of the Trinidad 
and Tobago Cancer Society who reported family history during 2010 - 2013 
 N = 520 Proportion 
Mean Age 55  
Age Range 20 - 59  
Ages   
20-29 41 0.07 
30-39 73 0.14 
40-49  128 0.25 
50-59 149 0.29 




Afro-Caribbean 198 0.31 
East Indian  161 0.38 
Mixed 161 0.31 
 
From that subset which reported family history, the proportion that met NIH/NCI 
criteria are shown in Table 5 below. The most common criteria reported in charts 
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was extensive family history (i.e. three or more first or second degree relatives 
diagnosed with breast cancer or ovarian cancer). This was followed by having at 
least one relative with a premenopausal breast cancer diagnosis (Table 6).  
In short, our results showed that 6.8% (123/1807) of the patients seen at the 
Trinidad and Tobago Cancer Society during 2010-2013 met the NIH/NCI criteria 
for referral to a genetic counselor to be further evaluated for genetic testing. 
Table 5: Number of Family history factors met by each client, as suggested by 
the NIH/NCI that are associated with an increased likelihood of having a BRCA 
mutation  
Number of NIH/NCI Family History Factors Met by 
Each Patient 
N= 520 Proportion 
1 105 0.20 
≥2 18 0.03 








Table 6: Family history criteria suggested by the NIH/NCI that are associated 
with an increased likelihood of having a BRCA mutation. 
 
  
Family history factors suggested by the NIH/NCI 
N   
Three or more first or second degree relatives diagnosed 
with breast cancer or ovarian cancer 
102 
Two first degree relatives diagnosed with breast cancer, 
with one below age 50 
83 
An immediate family member with bilateral breast cancer 
41 
Two or more first- or second-degree relatives diagnosed 
with ovarian cancer (regardless of age at diagnosis) 
35 
Breast cancer diagnosed in a male relative 
1 
Three or more first or second degree relatives diagnosed 
with breast cancer or ovarian cancer 
1 






Currently, the infrastructure for genetic counseling and testing in Trinidad and 
Tobago is limited in terms of accessibility, as it is only available in the private 
sector of local healthcare system for $1500-2000 USD. In addition, there are no 
trained genetic counselors within the country. However, Trinidad and Tobago has 
an average age of breast cancer diagnosis at about 45-50 years, which is 
significantly younger than the average age in the United States (61 years). The 
significant prevalence rate of HBOC mutations found in this study of 25.8% in 
breast cancer patients meeting NCCN criteria strongly suggests a major role of 
HBOC syndrome in young breast cancer patients in T&T.   More importantly, this 
high mutation rate also serves to emphasize the need for genetic counseling and 
testing services to be made obtainable in T&T. 
Our results are consistent with a previous study in T&T, which demonstrated a 
significantly high rate of BRCA mutations in the country.  This study tested 268 
unselected local patients for BRCA and PALB2 mutations. They found an 
estimated BRCA mutation rate of approximately 9.5%, and estimated the PALB2 
mutation rate at approximately 1.1% (16). Our study, which was the country’s first 
multi-gene panel investigation, further confirmed that indeed there are 
significantly higher rates of HBOC mutations in T&T, but that they go beyond 
BRCA and PALB2 within this population.  
To extend the importance of our findings to a region-wide scale, it should be 
noted that there have not been, until this moment, published studies investigating 
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the prevalence of the other HBOC mutations beyond BRCA in the Caribbean 
region. Therefore, our study marks the first of this kind to investigate HBOC 
mutations further than the sole BRCA-panel genetic testing.   
The significance and clinical relevance of extending beyond BRCA-focused 
testing in novel populations was demonstrated in our sample. For example, one 
of our patients who tested positive for PTEN reported having negative results 
with previous genetic testing, but this was done solely with a BRCA mutation 
panel. This caused her local physicians to rule out an underlying genetic 
influence to her cancer diagnoses, which in turn influenced her oncology care 
and prevention options for future cancers. Therefore, by widening the panel to 
incorporate more HBOC mutations (particularly for families who are not familiar 
with their genetic status), we can provide a more thorough screening to this 
population.  
It should be noted that in Trinidad and Tobago, there is an extensive ethnic 
variety, and our sample captured this appropriately. The local population of 
Trinidad and Tobago is mostly composed of African and East Indian descendants 
owing respectively to the slave-trade, and the arrival of indentured laborers from 
southern Asia seeking employment after the abolishment of slavery (17).  
Trinidad and Tobago also has a rich European colonizing history. The nation was 
first discovered by the Spanish explorer, Christopher Columbus. This was 
followed by the colonization of the Dutch, French and ultimately the British before 
the nation gained independence in the mid 20th century. In addition to these 
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many cultures present on the island, there is the native population which consists 
mostly of Arawaks and Carib ancestries (17). Our sample seemed to capture 
similar proportions to the population makeup. In addition, 39% of our participants 
identified as ‘mixed’, and did not wish to identify as being exclusively from one 
ethnicity.  
Interestingly, the genetic sequences found in the patients who tested positive 
reflected this ethnic diversity. In the 15 positive mutations, with the exception of 
the single mother/daughter pair, no two mutations were the same. Also, the 
genetic mutations seen in our sample were previously reported in studies 
regarding distinct populations from a wide variety of countries. For example, one 
patient, a 29 year old BRCA 1 carrier had a mutation (c.3756_3759delGTCT), 
and a  48 year old BRCA 1 carrier had a mutation (c.4327C>T). While both of 
these patients, self-identified as being of African descent,  their mutations have 
been well described as founder mutations in the French Canadian population in 
Quebec. This mutation was thought to have originated from France, and brought 
to Quebec during the 17th-18th century settlement period. Given Trinidad and 
Tobago’s past French colonization history, it can be assumed that similar 
settlements came to T&T from common origins in France (18) (19). 
Another mutation (c.1961dupA) is generally assumed to be a founder mutation in 
the Pakistani population (20), was found in a 35 year old BRCA 1 carrier, who 
self-identified as being of East Indian descent. One of our BRCA 2 carriers (48 
years at diagnosis) who identified as both Hispanic and African had the genetic 
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mutation (c.1763_1766delATAA) which has previously been found in unrelated 
Muslim families from Israel (21).   
Therefore, the rich cultural variation in Trinidad and Tobago can explain the 
broad diversity of genetic mutations seen in this sample. However, for an island 
population, which typically lends itself to geographic and reproductive isolation, it 
was initially hypothesized that T&T’s high mutation rate was attributed to some 
founder mutation effect within the country, such as that seen in Bahamas (11). 
But, this phenomenon would have resulted in little diversity in our genetic results. 
Thus, the extensive genetic variability in these mutations, does not lend itself to 
the founder effect hypothesis, but rather reflects the vast ethnic diversity that is 
present within T&T due to its past  migration patterns.  
In terms of distribution of the sample, most of the patients found to have 
mutations were from the northwestern and central parts of Trinidad (Figure 3), 
which were the areas closest to the National Radiotherapy Center, located in the 
northwest part of the island. As the main cancer institute for the public health-
sector, it provides complete oncology services for citizens, which includes 
surgeries, radiotherapy, chemotherapy and post-treatment surveillance. 
Therefore, it attracts patients from all over the country. This allowed us to gather 
a sample that was as close to an accurate representation of the national 
population as possible from a single location. Despite this, we still were limited in 




Another interesting aspect of the results was the family history reported by those 
enrolled in the study. In terms of family history, 67% BRCA mutation carriers 
reported having some form of family history of cancer, and 50% had at least one 
first degree relative with either breast, ovarian or prostate cancer, 42% had 
extensive family history of cancer of three or more first/second degree relatives 
with breast, ovarian or prostate cancer. However, 33% of the BRCA mutation 
carriers, reported having no family history, and met the criteria for the study 
solely based on age. It should be noted that many of the study participants were 
uncertain of their complete family history, as cancer remains a fairly taboo topic 
in the nation.  
Therefore, this showed that when evaluating risk to ascertain who needs genetic 
testing, perhaps T&T requires different selection criteria, perhaps one that relies 
less on family history. When considering cancer patients, the criteria should rely 
mostly on age of diagnosis parameters. Therefore, more research is needed to 
determine which criteria should be used for the local population of T&T to 
accurately evaluate who needs these services.  
The high prevalence of HBOC mutations in our breast cancer patient sample 
strongly indicates the need for genetic testing infrastructure in the country. This 
need was further demonstrated by our second aim which found that 6.8% of the 
women (with no previous cancer history) who visited the Trinidad and Tobago 
Cancer Society during 2010-2013, had family history criteria that recommended 
that they visit a genetic counselor to evaluate their risk of developing breast 
and/or ovarian cancer in the future (3) (22).  Of the total number of patient 
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records analyzed, 5.8% (105/1807) of the patients reported having one criteria, 
and 1% (18/1807) of the patients reported having two or more criteria. The 
second most common criteria reported in charts was having a relative with a 
premenopausal breast cancer diagnosis (usually before 50 years), which aligns 
with the high rates of young breast cancer diagnoses in Trinidad and Tobago. 
 However, it should be noted that despite family history being the most common 
factor, about 61% of the women had another factor that made them at high risk 
for having a genetic mutation. Therefore, this contributes to the previous 
deduction that a criteria specific for T&T needs to  go beyond the presence of 
family history when detecting high risk women in Trinidad and Tobago. The two 
least reported factors were: having male relatives affected with breast cancer, as 
well as, having multiple relatives with breast or ovarian cancer. It should be noted 
that this portion of the study did not inquire about prostate or pancreatic cancer in 
male relatives. Therefore, future investigations should contain family history 
questions that inquire beyond breast and ovarian cancers to attain a complete 
risk assessment.  
The Trinidad and Tobago Cancer Society was chosen as our single location to 
investigate the second aim because it is one of the major local non-profit 
organizations, and it attracts citizens from all over the country, similar to the 
National Radiotherapy Center. Therefore, it allowed us to gather a sample from a 




In summary, these two aims show that genetic counseling and testing should be 
accessible in Trinidad and Tobago for both cancer patients and unaffected 
citizens, as HBOC mutations are prevalent in the cancer patient population, and 
a number of women without cancer diagnoses meet the criteria for genetic 
counseling.  
Access can offer women preventative measures such as prophylactic surgeries 
(mastectomy and salpingo-oophorectomy), chemoprevention options and 
increased screenings, which have all been proven to lower mortality rates 
regardless of a previous cancer diagnosis (14) (13). Therefore, it is imperative 
that a cancer screening and prevention program be established in this country. 






Our data collection for patients was either done from chart records or from the 
patients themselves. Therefore, more fundamental clinical details of patients’ 
diagnoses could not be obtained in a timely manner. For example, tumor 
receptors were not automatically attained at the time of diagnosis in Trinidad and 
Tobago. In the public sector this can take weeks to months for the results to 
return. Therefore, many patients we recruited at the time did not have their tumor 
receptors on file. We hope to gather this information to complete our 
interpretations of the results, particularly with regard to the role of triple negative 
breast cancer and genetic mutation carriers within this population.  
Topics surrounding cancer are still very taboo in T&T’s culture. Even though 
there have been more awareness and educational campaigns, unfortunately, 
many family members do not share their diagnosis with those close to them. This 
impacted the study because some of our pedigrees for patients were incomplete 
due to uncertainty of family history. Some patients did share instances of 
unknown causes of death for family members, which were preceded by weight 
loss, abdominal pain and rapid deterioration. However, they were ultimately 
uncertain whether these were attributed to an underlying cancer diagnosis. 
Considering this aspect of the local culture, during genetic counseling sessions, 
patients were offered options to confidentially notify family members that they 




In addition, we did have some delay in the return of results, as initially there 
seemed to be a cultural barrier with telemedicine which limited the effectiveness 
of the post-test genetic counseling. For example, our first patient who tested 
positive for a genetic mutation did not appear to benefit fully from the 
telemedicine session, and seemed to have some difficulty understanding her 
results. This was perhaps due to most medicine in T&T being performed in-
person. Therefore, in order to ensure effective and safe return of the results, we 
needed to accommodate genetic counselors traveling to T&T to deliver some in-
person counseling. This delayed this portion of the study by approximately four 
months. However, the in-person return of the results were more beneficial, 
particularly to the patients who tested positive, as they had the most clinical 
impact from the results. 
As mentioned in the Discussion, Figure 3 shows that our sample mainly came 
from areas closest to the National Radiotherapy Center. This could possibly be 
because  we required that participants travel to northwestern Trinidad, which 
could have been a hindrance for potential participants. All Tobago participants 
needed to commute to Trinidad which required a flight or water ferry 
transportation. Given that Tobago has about a quarter of the country’s 
population, our sample may not have captured the prevalence adequately of this 
particular island, as only 3.4% (2/58) of the patients were from Tobago. 
Therefore, future studies need to expand to other oncology treatment sites 




Finally, our study intended to sample about 350 women at the National 
Radiotherapy Center. However, funding could only be obtained for 60 samples. 
Therefore, we hope to receive additional funding to continue pursuing research 






CONCLUSIONS AND FUTURE DIRECTIONS 
Trinidad and Tobago has one of the highest breast cancer rates in the Caribbean 
region. This disease represents 30% of all new female cancer cases and 24% of 
all female cancer related deaths. In addition, a large proportion of breast cancer 
cases in T&T appear to occur at a young age. HBOC can be associated with a 
younger age of breast cancer diagnosis. Therefore, we investigated the 
prevalence and spectrum of HBOC mutations in the local population of high risk 
breast cancer patients (by NCCN guidelines), and also investigated the 
proportion of women who met NIH/NCI criteria for further genetic counseling and 
testing.  
Through our sample, we found that for the women who met the NCCN 
guidelines,  approximately 25.8% had an HBOC mutations: 21% BRCA, 1.7% 
PTEN, 1.7% CHEK2 and 1.7% PALB2. In addition, approximately 6.8% of adult 
women (with no cancer diagnosis) who visited the T&T Cancer Society during 
2010-2013 met the criteria for further genetic counseling and evaluation 
according to U.S. guidelines.  
These two conclusions strongly suggest that genetic testing infrastructure needs 
to be established in this country in an accessible manner. Therefore, it is 
recommended that the government put policies and resources in place to 
facilitate this new addition to local oncology in the public system.  
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Future works in Trinidad and Tobago include the establishment of a high-risk 
clinic that promotes continued genetic testing and counseling to families of 
affected patients, and other high risk patients who are referred by local  
physicians. By using the framework provided by this research project, we are 
able to continue our partnership with Color Genomics and the local oncologists.  
It is our goal to continue assembling funding to help subsidize the cost of the test 
for patients, which will enhance accessibility. Ultimately, we hope that genetic 
counseling and testing would be implemented in the public healthcare sector, 
which can thereby remove the cost from patients entirely. With genetic testing as 
part of Trinidad and Tobago’s oncology regimen, there can be a reduction of 
breast cancer incidence and mortality rates throughout the nation, and this can 
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APPENDIX 1: LABORATORY METHODS FOR COLOR GENOMICS INC – 
GENETIC SEQUENCING OF SAMPLES 
“The Color Test is designed to assess clinically relevant mutations in 30 genes 
associated with hereditary cancer risk. Genomic DNA is extracted from a saliva 
sample using standard methods. Next Generation Sequencing libraries 
compatible with the Illumina platform are generated and enriched for the 30 
genes via a custom designed Agilent SureSelect bait library. DNA fragments 
enriched from these genes are retrieved and analyzed using 2x150 paired end 
sequencing with an Illumina NextSeq 500 instrument. After alignment to 
reference genome GRCh37.p12 (hg19), low quality and duplicate reads are 
removed and variants are detected with GATK Haplotypecaller. This test detects 
single nucleotide substitutions, small insertions and deletions, and copy number 
variations located in the DNA coding sequences, nearby flanking regions 
(+/20bp) and known splice regions in the genes targeted by the Color panel. Any 
exceptions to this are noted in the Limitations section. 
Variants are classified according to the standards and guidelines for sequence 
variant interpretation of the American College of Medical Genetics and Genomics 
(ACMG). Variant classification categories include pathogenic, likely pathogenic, 
variant of uncertain significance (VUS), likely benign, and benign. All variants are 
evaluated by a board certified medical geneticist or pathologist. Identified likely 
benign and benign variants are not reported. The presence of a VUS is always 
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reported, and the details are available upon request. All VUS and likely 
pathogenic variants are reviewed bi-annually for updates in the scientific 
literature. As part of the Color service, we will attempt to recontact the client if 
any reported variant’s classification changes. 
This test was developed and its performance characteristics determined by Color 
Genomics, a clinical laboratory accredited by the College of American 
Pathologists (CAP) and certified under the Clinical Laboratory Improvement 
Amendments (CLIA) to perform high-complexity testing (CAP #8975161 - CLIA 
#05D2081492). This test has received the European Conformity (CE) mark 
approval in compliance with the EU legislation. This test has not been cleared or 
approved by the United States Food and Drug Administration (FDA). The FDA 
does not require this test to go through premarket FDA review. This test is used 
for clinical purposes. It should not be regarded as investigational or for research. 
Genes APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, 
CDK4*, CDKN2A (p14ARF), CDKN2A (p16INK4a), CHEK2, EPCAM*, GREM1*, 
MITF*, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2*, POLD1*, POLE*, 
PTEN, RAD51C, RAD51D, SMAD4, STK11, TP5 3 
* These genes are only analyzed at specific locations (see Limitations). 
Limitations: This test aims to detect all clinically relevant variants within the 
genes analyzed (defined above). The majority of these genes are assessed for 
variants within all coding exons (+/- 20bp in the nearby flanking regions). Exons 
12-15 of PMS2 and homopolymer regions outside of the coding regions cannot 
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be reliably assessed with standard target enrichment protocols. For the CDK4, 
MITF, POLD1 and POLE genes, the elevated risk of cancer is associated with 
distinct functional genomics regions. The complete coding sequences of these 
genes are not reported, but instead only the following regions: CDK4 - 
chr12:g.58145429-58145431 (codon 24), MITF chr3:g.70014091 (including 
c.952G>A), POLD1 - chr19:g.50909713 (including c.1433G>A) and POLE - 
chr12:g.133250250 (including c.1270C>G). In EPCAM, only large deletions and 
duplications including the 3’ end of the gene are reported. These are the only 
variants known to silence the MSH2 gene and therefore increase risk of 
associated cancer. GREM1 is only analyzed for duplications in the upstream 
regulatory region. 
The test might have reduced sensitivity to detect insertions and deletions 
between approximately 40-250bp. While this test does detect large deletions and 
duplications, it is not designed to detect chromosomal aneuploidy or complex 
gene rearrangements such as translocations, large insertions, and inversions. It 
also does not reliably detect mosaicism. 
Color only reports findings within the genes that are on the panel. It is important 
to understand that there may be variants in those genes that current technology 
is not able to detect. Additionally, there may be genes associated with hereditary 
cancer risk whose clinical association has not yet been definitively established. 
The test may therefore not detect all variants associated with hereditary cancer 
risk. Additionally, in the unlikely event a variant is detected that is associated with 
a disorder or disease other than cancer, this information will be included in the 
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report. Genetic counseling and/or physician consultation may be warranted to 
ensure complete understanding of your test results. 
Environmental and other factors are thought to cause the majority of cancers. 
Consequently, tests that do not detect a pathogenic or likely pathogenic mutation 
do not eliminate an individual’s hereditary cancer risk and do not guarantee 
present or future health. In addition, the causes of cancer are multifactorial and 
can be influenced by both inherited and acquired genetic mutations, age, 
environment and various lifestyle choices. An individual’s risk of cancer is 
dependent upon each of these factors as well as family disease history. In very 
rare cases, such as circulating hematolymphoid neoplasm, allogeneic bone 
marrow transplant, or recent blood transfusion (within 7 days of testing), the 
results of germline DNA analysis may be complicated by somatic and/or donor 
mutations. 
Disclaimers: Color implements several safeguards to avoid technical errors, such 
as 2-dimensional barcoding and barcode scanning at several steps throughout 
the sequencing process. Color Genomics is not responsible for errors in 
specimen collection, transportation, and activation or other errors made prior to 
receipt at our laboratory. Due to the complexity of genetic testing, diagnostic 
errors, although rare, may occur due to sample mix-up, DNA contamination, or 
other laboratory operational errors. In addition, poor sample DNA quality and 
certain characteristics inherent to specific regions of an individual’s genomic DNA 
may limit the accuracy of results in those regions. 
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In the absence of an identified pathogenic or likely pathogenic mutation, several 
standard risk models may be employed to determine potential risk of breast 
cancer and guidelines displayed on this report. All risk estimation is approximate, 
sometimes cannot be specifically calculated, and is based on previously 
analyzed cohorts. Additionally, risk estimation may be incorrect if inaccurate 
personal or family history information is provided. An elevated risk of cancer is 
not a diagnosis and does not guarantee that a person will develop the disease.” 
(23) 
 
